LDLiang Dai

Liang Dai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liang Dai has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Ke-Neng Chen

    State Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department I of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China

    3 shared publications
  • Wan Wei

    First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China

    2 shared publications
  • Yan He

    First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China

    2 shared publications
  • Bin Zhang

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication
  • Dongbo Chen

    Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Beijing, China

    1 shared publication
  • Guohui Xu

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Effects of nutritional support during neoadjuvant therapy on perioperative outcome in esophageal cancer: a real-world cohort study

    by Yongbo Yang, Yan He, Wan Wei, Yaya Wu, Hong Chen, Yimei Gao, Wanpu Yan, Mengying Fan, Shaohua Ma, Zhen Liang, et al.

    Background: While postoperative nutritional support for esophageal cancer is well-documented, the impact of nutritional intervention during neoadjuvant therapy remains understudied. This study investigates the role of nutritional support during neoadjuvant therapy in improving perioperative outcomes for esophageal cancer patients. Methods: A retrospective analysis of 454 esophagectomy patients following neoadjuvant therapy was conducted. Patients were categorized into a nutrition effective group (weight maintenance or gain, n=304) and a control group (weight loss, n=150) according to their weight change after nutritional intervention. Preoperative nutritional status, therapy completion, adverse reactions, postoperative pathological outcomes, and complications were compared between groups. Results: Compared to the control group, the nutrition effective group demonstrated (I) improved nutritional status during neoadjuvant therapy with higher body mass index (BMI) changes (0.85±0.88 vs. −0.90±0.65 kg/m2, Pvs. 0.53±0.82, P=0.03); (II) higher neoadjuvant therapy completion rate (82.9% vs. 74.7%, P=0.04); (III) lower incidence of grade 3 or higher adverse reactions during neoadjuvant therapy (13.8% vs. 21.3%, P=0.04); and (IV) reduced postoperative anastomotic leakage rates (10.2% vs. 17.3%, P=0.03). No significant differences were observed in postoperative hospital stay, grade 3 or higher complications, or pathological response rates [tumor regression grade (TRG) ≤2, major pathological remission (mPR), and pathological complete remission (pCR)]. Conclusions: Nasogastric tube feeding plays a pivotal role in effective nutritional support during neoadjuvant therapy. Effective nutritional intervention not only improves preoperative nutritional status and enhances neoadjuvant therapy completion but also mitigates grade 3 or higher adverse events and reduces the incidence of anastomotic leakage. Additionally, it may potentially contribute to improved postoperative pathological remission.


  • Early Contrast-Enhanced MR for Diagnosing Complete Tumor Response of Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy: A Retrospective Comparative Study

    by Yan-Jie Shi, Shuo Yan, Xin Yang, Zhen Guan, Xiao-Ting Li, Lin-Lin Wang, Liang Dai, Ying-Shi Sun

    This study assessed the performance of early contrast-enhanced magnetic resonance (ECE-MR) in the detecting of complete tumor response (ypT0) in patients w


  • Open Access

    Dietary habits and nutrition status in esophageal cancer patients after esophageal reconstruction

    by Yan He, Ya-Ya Wu, Wan Wei, Yong-Bo Yang, Yao Lin, Liang Dai

    Background: Surgery is the cornerstone of the treatment of esophageal cancer (EC). This study is to evaluate the dietary habits and nutrition status in EC patients who underwent esophagectomy followed by esophageal reconstruction. Methods: This retrospective study included patients with EC who underwent esophagectomy followed by esophageal reconstruction in the Department of Thoracic Surgery I of Peking University Cancer Hospital between February 2014 and December 2018. The primary outcomes were dietary habits and nutrition status. The secondary outcomes were gastrointestinal symptoms and quality of life (QoL). Results: A total of 346 patients were included. At 30 months after the operation, 90.2% of the patients had recovered to regular dietary habits, 72.8% of patients had a restored frequency of preoperative regular food intake, 2.3% of the patients ate more than six times a day, and 0.6% had semi-liquid food because of bad teeth. The nutrition status remained stable after 6 months postoperatively and recovered slightly 1 year after the surgery. At 30 months after the operation, the most common gastrointestinal symptoms were reflux (38.4%), dysphagia (15.3%), hoarseness (11.8%), abdominal distension (6.6%), diarrhea (2.9%), and nausea and vomiting (2.3%). According to the European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-OG 25 (EORTC QLQ-OG 25), the factors that affected the life quality of patients during follow-up were anxiety, reflux, and dietary limitations. Conclusions: Most patients with EC who underwent esophageal reconstruction recovered to regular dietary habits and stable nutrition status, while some may still suffer from gastrointestinal symptoms, anxiety, and dietary limitations.


  • Open Access

    IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor

    by Meichen Liu, Wanpu Yan, Dongbo Chen, Jiancheng Luo, Liang Dai, Hongsong Chen, Ke-Neng Chen

    PD-(L)1 inhibitor could improve the survival of locally advanced esophageal cancer (ESCA) patients, but we cannot tailor the treatment to common biomarkers. WNT signaling activation was associated with primary resistance to immunotherapy. In this study, we used our two clinical cohorts (BJCH n = 95, BJIM n = 21) and three public cohorts to evaluate and verify a new immunotherapeutic biomarker based on WNT signaling in ESCA patients. Our findings showed that WNT signaling-related genes stratified TCGA patients into Cluster 1, 2, and 3, among which, Cluster 3 had the worst prognosis. The most up- and down-regulated genes in Cluster 3 were IGFBP1 and WNT3A. Further analysis validated that IGFBP1hiWNT3Alo ESCA patients had significantly poor RFS and OS in the TCGA and BJCH cohorts. Interestingly, IGFBP1hiWNT3Alo patients had a good response and prognosis with immunotherapy in three independent cohorts, exhibiting better predictive value than PD-L1 expression (signature AUC = 0.750; PD-L1 AUC = 0.571). Moreover, IGFBP1hiWNT3Alo patients may benefit more from immunotherapy than standard treatment (p = 0.026). Immune cell infiltration analysis revealed a significant increase in DC infiltration in IGFBP1hiWNT3Alo patients post-immunotherapy (p = 0.022), which may enhance immune response. The IGFBP1hiWNT3Alo signature could predict patients who benefited from PD-(L)1 inhibitor treatment and may serve as a biomarker in ESCA.


  • Open Access

    Video mediastinoscopy-assisted superior mediastinal dissection in the treatment of thyroid carcinoma with mediastinal lymphadenopathy: preliminary results

    by Yuntao Song, Liang Dai, Guohui Xu, Tianxiao Wang, Wenbin Yu, Keneng Chen, Bin Zhang

    Background: Mediastinal lymph node metastases (MLNM) are not rare in thyroid cancer, but their treatment has not been extensively studied. This study aimed to explore the preliminary application of video mediastinoscopy-assisted superior mediastinal dissection in the diagnosis and treatment of thyroid carcinoma with mediastinal lymphadenopathy. Materials and methods: We retrospectively reviewed the clinical pathologic data and short-term outcomes of thyroid cancer patients with suspicious MLNM treated with video mediastinoscopy-assisted mediastinal dissection at our institution from 2017 to 2020. Results: Nineteen patients were included: 14 with medullary thyroid carcinoma and five with papillary thyroid carcinoma. Superior mediastinal nodes were positive in nine (64.3%) patients with medullary thyroid carcinoma and in four (80.0%) patients with papillary carcinoma. No fatal bleeding occurred. There were three cases of temporary recurrent laryngeal nerve (RLN) palsy postoperatively, one of which was bilateral. Four patients had temporary hypocalcemia requiring supplementation, one had a chyle fistula, and one developed wound infection after the procedure. Postoperative serum molecular markers decreased in all patients. One patient died of cancer while the other 18 patients remained disease-free, with a median follow-up of 33 months. Conclusion: Video mediastinoscopy-assisted superior mediastinal dissection can be performed relatively safely in patients with suspicious MLNM. This diagnostic and therapeutic approach may help control locoregional recurrences.